ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

10,38

12-ноября-24 14:13:26

15 мин. задержка

Акции

-0,46

-4,24%

Сегодняшний диапазон

10,37 - 10,74

ISIN

N/A

Источник

NASDAQ

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

22 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

09 июл 2024 15:53:01 Источник Nasdaq GlobeNewswire
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis

09 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 июл 2024 15:00:00 Источник Nasdaq GlobeNewswire
Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

10 июн 2024 13:30:00 Источник Nasdaq GlobeNewswire
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 июн 2024 15:00:00 Источник Nasdaq GlobeNewswire
Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

03 июн 2024 07:00:00 Источник Nasdaq GlobeNewswire
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update

14 май 2024 15:00:00 Источник Nasdaq GlobeNewswire
Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

13 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 май 2024 15:00:00 Источник Nasdaq GlobeNewswire
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

29 апр 2024 15:00:00 Источник Nasdaq GlobeNewswire
Arcutis Appoints David Topper as Chief Financial Officer

10 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 апр 2024 15:00:00 Источник Nasdaq GlobeNewswire
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference

28 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire
Arcutis Promotes Todd Tucker to Chief Human Resources Officer

11 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

10 мар 2024 15:00:00 Источник Nasdaq GlobeNewswire
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

09 мар 2024 15:00:00 Источник Nasdaq GlobeNewswire
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 мар 2024 15:00:00 Источник Nasdaq GlobeNewswire
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

04 мар 2024 15:00:00 Источник Nasdaq GlobeNewswire
Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting

04 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.